---
document_datetime: 2023-09-21 18:33:42
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/zavesca-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: zavesca-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 0.3248373
conversion_datetime: 2025-12-27 22:09:39.603884
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## STEPS TAKEN AFTERGRANTING THE MARKETING AUTHORISATION

For procedures finalised after 1 April 2003 please refer to module 8B .

- On 4 December 2002, the original Marketing Authorisation Holder, Oxford GlycoSciences (UK) Ltd, submitted to the EMEA an application for the transfer of the Marketing Authorisation for the medicinal product to Actelion Registration Ltd. On 16 December 2002, the EMEA Opinion was adopted and sent to the European Commission. The respective Commission Decision was issued on 3 February 2003. The date chosen by the two companies involved for full implementation of the transfer is the date of notification of the Commission Decision (5 February 2003).